HC Wainwright Boosts Earnings Estimates for ADMA Biologics

ADMA Biologics, Inc. (NASDAQ:ADMA) – Stock analysts at HC Wainwright lifted their FY2024 earnings per share estimates for shares of ADMA Biologics in a research note issued on Friday, November 8th. HC Wainwright analyst R. Selvaraju now forecasts that the biotechnology company will post earnings of $0.55 per share for the year, up from their previous estimate of $0.49. HC Wainwright has a “Buy” rating and a $26.00 price objective on the stock. The consensus estimate for ADMA Biologics’ current full-year earnings is $0.51 per share. HC Wainwright also issued estimates for ADMA Biologics’ Q4 2024 earnings at $0.19 EPS, Q1 2025 earnings at $0.20 EPS, Q2 2025 earnings at $0.21 EPS, Q3 2025 earnings at $0.22 EPS and Q4 2025 earnings at $0.24 EPS.

A number of other equities analysts also recently weighed in on the stock. Raymond James lifted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th.

ADMA Biologics Stock Down 3.1 %

Shares of NASDAQ ADMA opened at $21.78 on Monday. The company’s 50 day moving average price is $18.22 and its 200-day moving average price is $14.06. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics has a 52-week low of $3.60 and a 52-week high of $23.64. The company has a market capitalization of $5.08 billion, a P/E ratio of 78.75 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a return on equity of 59.29% and a net margin of 17.80%. During the same period in the previous year, the firm earned $0.01 earnings per share.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Quest Partners LLC acquired a new position in shares of ADMA Biologics during the second quarter valued at about $29,000. Hollencrest Capital Management bought a new position in ADMA Biologics in the 3rd quarter valued at about $30,000. EntryPoint Capital LLC acquired a new position in ADMA Biologics during the 1st quarter valued at about $31,000. Larson Financial Group LLC bought a new stake in ADMA Biologics during the 3rd quarter worth approximately $31,000. Finally, CWM LLC raised its stake in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after purchasing an additional 4,367 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the transaction, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 466,900 shares of company stock worth $8,224,121 in the last quarter. Company insiders own 3.70% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.